Tracked deals
19
19 tracked deals across 2020-2026.
Biotechnology Buyers & Acquisitions in New York
Buyer mix
Strategic-led
19 strategic · 4 pe
Top trend
Volume peaked in 2022
5 tracked deals announced in 2022.
Primary Insight
What Stands Out
- Clinical-stage neuroscience and neuropsychiatry appear in recent deals, including acquisitions involving rapid-acting neuroplastogens and treatments for PTSD.
- Contingent economics show up in multiple transactions, including contingent value rights and milestone payments alongside upfront consideration.
- Translational and enabling platforms are a recurring theme: stem cell automation/high-throughput research, antibody oncology assets, and cardiac 3D tissue modeling.
- Cancer and rare disease capabilities are reflected in acquisitions such as SERB’s purchase of antibody-based oncology assets.
- New York-based targets range from clinical biotech to research-model and molecular biomarker businesses, reinforcing the state’s broad biotech base.
Build a buyer list for your Biotechnology deal
Find buyers actively acquiring biotechnology companies.
Find buyers like these for your dealBuyer Snapshot
Top Buyers
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| Eli Lilly and Company | 3 | Global pharmaceutical company focused on discovery, devel... | Strategic |
| ATAI Life Sciences AG | 1 | Biotechnology company builder and investor focused on dev... | Strategic |
| Apeiron Investment Group, Ltd | 1 | Investor that entered voting and support agreements to he... | Mixed |
| Avista Capital Partners | 1 | Private equity firm focused exclusively on healthcare inv... | PE |
| Biocare Medical | 1 | Developer and manufacturer of automated immunohistochemis... | Strategic (PE-backed) |
| Cole-Parmer | 1 | Global manufacturer of proprietary products for fluidics,... | Strategic (PE-backed) |
| GHO Capital Partners LLP | 1 | European specialist healthcare private equity investor th... | PE |
| GTCR | 1 | Leading private equity firm focused on investing in growt... | PE |
| Granata Bio | 1 | U.S.-based biopharmaceutical company focused on reproduct... | Strategic |
| Kindbody | 1 | Operator of fertility clinics and employer-focused fertil... | Strategic |
Acquisition Volume in Biotechnology in New York by Year
Last 6 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
- Buyer
- Eli Lilly and Company, Apeiron Investment Group, Ltd
- Target
- AtaiBeckley Inc.
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
Eli Lilly and Company has entered into a definitive agreement to acquire AtaiBeckley, a clinical-stage biopharmaceutical company developing rapid-acting neuroplastogens for mental health conditions. Under the terms, Lilly will pay $6.75 per share in cash plus up to $2.50 per share in contingent value rights tied to development and regulatory milestones for BPL-003 and VLS-01, with the deal expected to close in the third quarter subject to customary approvals. A later update indicates Lilly has completed the acquisition following AtaiBeckley shareholder approval, integrating the clinical-stage pipeline into Lilly’s neuroscience R&D organization.
-
March 27, 2026
- Buyer
- Otsuka Pharmaceutical Co., Ltd., Otsuka America, Inc., Otsuka America Pharmaceutical, Inc.
- Target
- Transcend Therapeutics, Inc.
- Seller
- Transcend shareholders
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
Otsuka Pharmaceutical Co., Ltd. entered into an agreement to acquire clinical-stage biotech company Transcend Therapeutics, which is developing rapid-acting treatments for neuropsychiatric disorders, including its lead program TSND-201 (methylone) for PTSD. Otsuka would pay $700 million upfront at closing and up to $525 million in contingent milestone payments, with completion expected in Q2 2026; the acquisition has since been completed.
-
October 22, 2025
- Buyer
- The Jackson Laboratory
- Target
- New York Stem Cell Foundation (NYSCF)
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
The Jackson Laboratory (JAX) has completed its acquisition of the New York Stem Cell Foundation (NYSCF), combining JAX's genetics and preclinical modeling expertise with NYSCF's stem cell automation and high-throughput research platform. The unified nonprofit aims to create an integrated discovery platform that accelerates translational research by linking genomics, stem cell biology, and data/AI capabilities.
-
September 16, 2025
- Buyer
- SERB Pharmaceuticals
- Target
- Y-mAbs Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
SERB Pharmaceuticals completed its acquisition of Y-mAbs Therapeutics following a tender offer and statutory merger, making Y-mAbs a wholly owned subsidiary and delisting it from Nasdaq. The deal adds Y-mAbs' antibody-based oncology assets — including Danyelza (naxitamab-gqgk) — to SERB's rare disease and rare oncology portfolio to expand its commercial capabilities in pediatric and rare cancers.
-
April 29, 2025
- Buyer
- Granata Bio
- Target
- Oviva Therapeutics
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
Granata Bio has acquired Oviva Therapeutics, a women's health biotech developing OVI-586, a first-in-class therapeutic aimed at extending ovarian function and improving reproductive outcomes. The acquisition expands Granata's fertility and women's health pipeline and will advance OVI-586 toward further development for applications including menopause, contraception, and in vitro fertilization (IVF).
-
July 14, 2023
- Buyer
- Eli Lilly and Company
- Target
- Versanis Bio
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
Eli Lilly has entered into a definitive agreement to acquire Versanis Bio, a private clinical-stage biopharmaceutical company developing bimagrumab for cardiometabolic diseases and obesity. The deal could deliver up to $1.925 billion to Versanis shareholders and is intended to combine Versanis’ activin/myostatin biology expertise with Lilly’s incretin portfolio to advance combination treatments for obesity and related cardiometabolic conditions.
-
November 23, 2022
- Buyer
- Biocare Medical, GHO Capital Partners LLP
- Target
- Empire Genomics
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Addon
Biocare Medical, a GHO Capital-backed provider of automated IHC and FISH instrumentation and reagents, has acquired Empire Genomics, a designer and manufacturer of FISH/CISH probes and molecular biomarkers. The deal expands Biocare's molecular portfolio (bringing over one million biomarkers) and adds rapid biomarker development capabilities to accelerate cancer research and diagnostics.
-
November 16, 2022
- Buyer
- Kriya Therapeutics, Inc.
- Target
- Redpin Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
Kriya Therapeutics has acquired Redpin Therapeutics, a preclinical New York City–based gene therapy company with a proprietary chemogenetics platform. The deal establishes Kriya's neurology therapeutic-area portfolio by adding Redpin’s lead programs targeting epilepsy and trigeminal neuralgia, and brings chemogenetic capability to Kriya’s gene therapy engine.
-
November 1, 2022
- Buyer
- Avista Capital Partners
- Target
- Taconic Biosciences
- Seller
- H.I.G. Capital
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
Avista Capital Partners has acquired Taconic Biosciences from H.I.G. Capital. Taconic, a Rensselaer, New York–based provider of genetically engineered murine research models and related preclinical services, will leverage Avista's healthcare investing expertise to pursue organic growth and strategic acquisitions in the GEMs market.
-
June 7, 2022
- Buyer
- Kindbody
- Target
- Phosphorus Labs
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
Kindbody has acquired Phosphorus Labs, a preventative genomics and clinical genetic-testing company, including Phosphorus’s 8,000 sq. ft. reference laboratory in Secaucus, New Jersey. The acquisition brings genetic testing and carrier screening capabilities in-house as Kindbody creates its KindLabs division to integrate diagnostics into its end-to-end fertility and family-building care.
-
April 5, 2022
- Buyer
- Valo Health
- Target
- TARA Biosystems
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
Valo Health has acquired TARA Biosystems, a New York City–based company specializing in human 3D tissue engineering and cardiac disease modeling, to create an integrated cardiovascular drug discovery and development platform. The deal combines TARA's in vitro cardiac models with Valo's Opal computational platform to expand Valo's capabilities in cardiovascular drug discovery and accelerate development of new therapies.
-
May 28, 2021
- Buyer
- Zymergen Inc.
- Target
- Lodo Therapeutics Corporation
- Seller
- Accelerator Life Science Partners I (ALSP I)
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
Zymergen Inc. acquired Lodo Therapeutics Corporation from Accelerator Life Science Partners (ALSP), integrating Lodo’s metagenomic natural‑product discovery platform into Zymergen’s technology stack. ALSP had been an investor and operator of Lodo following a $17 million Series A and a collaboration with Genentech; the financial terms of the deal were not disclosed by ALSP in its announcement.
-
Welsh, Carson, Anderson & Stowe Commits $250M to Kiniciti Platform for Cell & Gene Therapy EcosystemFebruary 1, 2021
- Buyer
- Welsh, Carson, Anderson & Stowe
- Target
- Kiniciti
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Growth capital
Welsh, Carson, Anderson & Stowe (WCAS) committed up to $250 million to a strategic partnership with newly-formed Kiniciti, a platform that will invest in non-therapeutic companies supporting the cell and gene therapy ecosystem. The capital will support Kiniciti's flexible investment model (control, growth equity and significant minority stakes) to scale companies that provide process, production, materials and delivery capabilities for CGT.
-
January 12, 2021
- Buyer
- Cole-Parmer, GTCR
- Target
- ZeptoMetrix
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Addon
GTCR’s portfolio company Cole-Parmer has acquired ZeptoMetrix, a Buffalo-based developer and manufacturer of quality control standards and verification panels for molecular diagnostic testing. The acquisition expands Cole-Parmer’s life sciences quality controls and reference standards portfolio and strengthens its capabilities in infectious disease and molecular diagnostics.
-
December 15, 2020
- Buyer
- Eli Lilly and Company
- Target
- Prevail Therapeutics Inc.
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
Eli Lilly and Company announced a definitive agreement to acquire Prevail Therapeutics for $22.50 per share in cash, plus a non-tradable contingent value right (CVR) worth up to $4.00 per share, for total consideration of up to approximately $1.04 billion. The acquisition is intended to establish a gene therapy program within Lilly anchored by Prevail’s AAV9-based neuroscience pipeline. Lilly expects the transaction to close in the first quarter of 2021, subject to customary closing conditions and regulatory approvals.
-
October 30, 2020
- Buyer
- Sana Biotechnology, Inc.
- Target
- Oscine Corp.
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
Sana Biotechnology announced the acquisition of Oscine Corp., integrating Oscine’s glial progenitor cell program and technologies into Sana’s broader platform to advance CNS therapies. Steve Goldman, Oscine’s scientific founder, joined Sana as Head of CNS Therapy; terms of the acquisition were not disclosed.
-
July 9, 2020
- Buyer
- ATAI Life Sciences AG
- Target
- Kures
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
ATAI Life Sciences AG acquired a majority stake in New York–based pharmaceutical company Kures to advance Kures' mitragynine-derived therapeutic candidates (KUR-101 and KUR-002) targeting pain and opioid use disorder. The deal brings Kures onto ATAI's biotech platform and appoints ATAI CSO Srinivas Rao as Kures CEO to accelerate development and integrate the assets into ATAI's mental-health-focused pipeline.
-
June 29, 2020
- Buyer
- Repligen Corporation
- Target
- Engineered Molding Technology (EMT)
- Seller
- Michael Pandori
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
Repligen Corporation agreed to acquire Engineered Molding Technology (EMT), an Albany, New York manufacturer of single-use silicone assemblies, connectors and tubing used in biologic drug manufacturing. The purchase expands Repligen’s single-use ProConnex flow-path capabilities, streamlines its supply chain for ATF, and aims to deliver faster lead-times and a more integrated offering for biopharma and CDMO customers; terms were not disclosed and the deal was expected to close in Q3 2020.
-
February 28, 2020
- Buyer
- L2P Research, LLC
- Target
- METIS Research Laboratories
- Industry
- Biotechnology
- Location
- New York, United States
- Type
- Buyout
L2P Research, LLC has acquired METIS Research Laboratories, a Ronkonkoma, New York-based preclinical CRO that provides radiotracer, radioligand binding, ADME/PK and QWBA services. The acquisition adds a GLP-compliant 5,000 sq. ft. facility and expands L2P's preclinical capabilities for pharma, biotech and academic customers.
Build a buyer list for your Biotechnology deal
Find buyers actively acquiring biotechnology companies.
Frequently Asked Questions
Which acquirers are most active in New York biotechnology deals on this page?
Recurring acquirers include Eli Lilly and Company, Granata Bio, Sana Biotechnology, Inc., The Jackson Laboratory, Kriya Therapeutics, Inc., Apeiron Investment Group, Ltd, ATAI Life Sciences AG, and Valo Health.
Do these New York biotech acquisitions typically include milestone or contingent payments?
Yes—several transactions include contingent value rights or milestone payments in addition to upfront consideration (for example, in deals involving Eli Lilly and Company and Otsuka Pharmaceutical Co., Ltd.).
What kinds of biotech technologies are being added through acquisitions in New York?
Themes include clinical-stage therapeutic pipelines, stem cell automation and high-throughput research platforms, antibody-based oncology assets, molecular biomarker/probe development, gene therapy platforms, and 3D tissue/cardiac disease modeling.
Are the deals on this page limited to drug developers?
No. They also include acquisitions of research and diagnostics-enabling businesses—such as molecular biomarker and probe manufacturers, genetically engineered murine research model providers, and preventative genomics/testing companies.
Related Acquisition Pages
Biotechnology Buyers & Acquisitions
Biotechnology Buyers & Acquisitions in Canada
Private Equity-Backed Biotechnology Buyers
Biotechnology Acquisitions in 2026
Biotechnology Acquisitions in 2025
Biotechnology Acquisitions in 2023
Biotechnology Acquisitions in 2022
Biotechnology Acquisitions in 2021
Biotechnology Acquisitions in 2020
Acquisitions in New York
Private Equity-Backed Acquisitions in New York
Acquisitions in New York in 2026